Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

Zentalis Presents Positive Phase 1b MUIR Data for Azenosertib in PROC

Zentalis Pharmaceuticals announced encouraging Phase 1b MUIR trial data for its investigational WEE1 inhibitor, azenosertib, in combination with paclitaxel, for patients with platinum-resistant ovarian cancer (PROC). Presented at the 2026 ASCO Annual Meeting, the results from 46 heavily pre-treated patients showed a manageable safety profile and promising clinical activity. Across all dose cohorts, the combination achieved an overall response rate (ORR) of 39.1% and a median progression-free survival (PFS) of 7.3 months. Notably, the 250 mg QD 5:2 intermittent dose cohort demonstrated a 50.0% ORR and a median duration of response (DOR) of 9.2 months, suggesting an optimal therapeutic index. These findings support further evaluation of azenosertib-taxane combinations in ovarian cancer.

• The Phase 1b MUIR trial demonstrated encouraging clinical activity for azenosertib plus paclitaxel in 46 heavily pre-treated patients with platinum-resistant ovarian cancer. The all-comer population achieved an overall response rate (ORR) of 39.1% (95% CI: 25.1–54.6) and a median progression-free survival (PFS) of 7.3 months (95% CI: 3.7–7.5). These results compare favorably to historical paclitaxel monotherapy, which typically shows an ORR of approximately 30% and a median PFS of around 4 months in this setting.
• Within the study, the 250 mg intermittent (5 days on, 2 days off) dose cohort, comprising 12 patients, exhibited a potentially optimal therapeutic index. This specific cohort achieved a 50.0% ORR (95% CI: 21.1–78.9), including one complete response, and a median duration of response (DOR) of 9.2 months (95% CI: 3.8–NE). The clinical benefit rate (CBR) for this cohort was 66.7%, highlighting durable responses in a challenging patient population.
• The combination of azenosertib and paclitaxel showed a manageable safety profile across all four dose cohorts (n=46). The most common all-grade treatment-related adverse events (TRAEs) included fatigue (60.9%), anemia (58.7%), nausea (52.2%), and neutropenia (50.0%). The most frequent Grade ≥3 TRAEs were neutropenia (30.4%) and anemia (19.6%), with high-grade fatigue and nausea occurring in less than 10% of patients. Approximately 20% of patients experienced serious TRAEs, and 32.6% discontinued due to adverse events, with about half continuing azenosertib monotherapy.
• Interestingly, the clinical activity of azenosertib plus paclitaxel appeared similar regardless of Cyclin E1 status. In Cyclin E1-positive patients, ORR was 41.4% and median PFS was 7.3 months, while in Cyclin E1-negative patients, ORR was 35.7% and median PFS was 5.4 months. This suggests that Cyclin E1 biomarker status may not be as critical for benefit when azenosertib is combined with a cytotoxic agent like paclitaxel, which induces replication stress, broadening the potential patient population for this combination.

Why New Options are Crucial for Platinum-Resistant Ovarian Cancer

Platinum-resistant ovarian cancer presents formidable therapeutic challenges, with unsatisfactory response rates to standard chemotherapy and correspondingly low survival outcomes. Up to 80% of patients who initially respond to platinum-based therapy eventually develop resistance, creating a substantial unmet medical need for effective treatment options.

• Poor clinical outcomes and limited treatment efficacy - The 5-year survival rate is less than 40% for advanced ovarian cancer, with FIGO stages III and IV showing particularly dismal rates of 39% and 17% respectively, while recent trials have mostly yielded negative outcomes with no clinically significant improvements in progression-free or overall survival since bevacizumab approval

• Complex and evolving resistance mechanisms - Platinum resistance involves multifactorial intracellular mechanisms including restoration of homologous recombination repair, reduced platinum accumulation, blocked cellular replication, and inhibition of apoptosis, which act in concert with immunosuppressive, angiogenic and stromal changes in the tumor microenvironment

• Molecular stratification limitations - Current molecular stratification approaches lack prognostic and predictive validity, constrained by the extreme genomic complexity of high-grade serous ovarian cancer and significant tumor heterogeneity that complicates treatment selection

• Disappointing immunotherapy results - Single agent checkpoint inhibitors have shown disappointing results in clinical trials, with the role of immunotherapy in platinum-resistant ovarian cancer remaining undefined despite extensive investigation

• Drug delivery and toxicity challenges - Antibody-drug conjugates face obstacles including antigen heterogeneity, off-target toxicity, and emerging resistance mechanisms, while platinum-based drugs continue to pose problems with drug resistance and severe side effects

• Peritoneal microenvironment complexity - The peritoneal tumor microenvironment plays a crucial role in platinum resistance through interactions involving extracellular matrix, ascitic fluid, mesothelial cells, and various immune cell populations including tumor-associated macrophages, neutrophils, and T-regulatory cells

Azenosertib Plus Paclitaxel Shows Promise in MUIR Trial

Recent clinical studies in platinum-resistant ovarian cancer demonstrate promising advances across multiple therapeutic approaches, including immunotherapy combinations, antibody-drug conjugates, and novel targeted therapies. These trials highlight the evolving treatment landscape with improved efficacy outcomes and manageable safety profiles.

Azenosertib's Place in the Evolving PROC Treatment Landscape

Recent evidence demonstrates that participation in investigational therapy trials for platinum-resistant ovarian cancer provides significant survival advantages compared to standard-of-care treatments. The most compelling data comes from a 2023 study of 305 patients with recurrent platinum-resistant disease, where clinical trial participants achieved a median overall survival of 13.8 months versus 10.5 months for those receiving standard care (adjusted hazard ratio 1.46, 95% CI 1.04-2.05, P=0.028). This survival benefit was maintained on multivariable analysis controlling for key prognostic factors including comorbidities, stage, and germline mutational status. Earlier studies corroborate this trend, with trial participants consistently demonstrating superior outcomes, including a 2009 analysis showing median overall survival of 46 versus 25 months for investigational versus standard treatments.

The current treatment landscape for platinum-resistant ovarian cancer remains challenging, with standard-of-care options including topotecan, pegylated liposomal doxorubicin, gemcitabine, and oral etoposide providing only modest survival benefits. Recent trials in this setting have predominantly yielded negative results, with no clinically significant improvements in progression-free or overall survival since bevacizumab's approval in combination with chemotherapy. Notably, biologic and targeted therapies such as bevacizumab and PARP inhibitors, originally approved for platinum-resistant disease, have since been withdrawn from this indication and repositioned for upfront or platinum-sensitive settings due to limited efficacy.

Novel investigational approaches currently under evaluation include innovative drug delivery methods such as PIPAC (Pressurized IntraPeritoneal Aerosol Chemotherapy), which offers superior tissue penetration while avoiding typical systemic chemotherapy toxicities including alopecia, peripheral neurotoxicity, and myelosuppression. The focus has shifted toward biomarker-directed treatment and enhanced patient selection strategies, which may provide greater success in identifying effective novel therapies. While multiple agents demonstrate biological activity in platinum-resistant disease, an optimal evidence-based therapeutic strategy has yet to be established, emphasizing the continued importance of clinical trial participation for this challenging patient population.

Azenosertib's Intermittent Dosing: A New Path in Platinum-Resistant Ovarian Cancer

The recent Phase 1b MUIR trial data for Zentalis' azenosertib in platinum-resistant ovarian cancer (PROC) marks a potentially significant step forward in a disease area with substantial unmet needs. WEE1 kinase inhibitors like azenosertib target a critical cell-cycle checkpoint, forcing cancer cells with compromised DNA damage repair, often due to prevalent TP53 mutations in ovarian cancer, to prematurely enter mitosis. This mechanism is particularly compelling when combined with DNA-damaging agents such as paclitaxel, as preclinical research has demonstrated enhanced cell killing when WEE1 inhibition is paired with taxanes. The reported 39.1% overall response rate and 7.3 months median progression-free survival in heavily pre-treated patients are encouraging, especially considering the challenging nature of PROC.

A key takeaway from this announcement is the identification of an intermittent 250 mg QD 5:2 dosing regimen, which yielded a 50.0% ORR and a 9.2 months median duration of response. This optimized dosing strategy is crucial, as prior studies with other WEE1 inhibitors, such as adavosertib, have highlighted tolerability as a significant hurdle, with high rates of Grade ≥3 adverse events like myelosuppression, diarrhea, and fatigue often leading to treatment discontinuations. Zentalis' ability to achieve a "manageable safety profile" while maintaining robust efficacy with this intermittent schedule could be a differentiating factor.

However, several considerations remain. While WEE1 inhibition holds promise, the field has grappled with consistently identifying predictive biomarkers for patient selection, despite evidence suggesting activity in TP53-mutant, BRCA-mutant, or CCNE1-amplified tumors. Furthermore, the potential for adaptive resistance, as observed with PI3K/AKT pathway activation in long-term resistant ovarian cancer models, underscores the need for sustained efficacy and potentially further combination strategies. Future studies will need to confirm these promising results in larger cohorts, further characterize the long-term safety profile, and potentially refine patient selection strategies to maximize clinical benefit in this challenging patient population.